ECO2023 Newsletter Day Two: Nearly half of adolescents using semaglutide in trial dropped below the clinical cutoff for obesity

ECO2023 Newsletter Day Two: Nearly half of adolescents using semaglutide in trial dropped below the clinical cutoff for obesity

Presentation AD06.04 1700-1715H Thursday, The Auditorium

A new secondary analysis of the STEP TEENS trial presented at this year’s ECO and published in the journal Obesity shows that almost half (45%) of the adolescents assigned to semaglutide in the trial managed to lose enough weight to drop below the clinical cutoff for obesity.

The study, led by Dr. Aaron S. Kelly, Co-Director of the Center for Pediatric Obesity Medicine at the University of Minnesota, Minneapolis, MN, USA, and colleagues, also showed almost three quarters (74%) moved down by at least one weight category.

The full STEP TEENS trial, published in 2022 in NEJM, showed the efficacy of semaglutide in helping adolescents lose weight. In this secondary analysis of the STEP TEENS trial, the authors examined the effect of semaglutide treatment on improvement in body mass index (BMI) categories.

Adolescents (aged 12 to under 18 years) with BMI in the highest 5% were included in this analysis. Participants were randomised 2:1 to once-weekly subcutaneous semaglutide 2.4 mg (n=134) or placebo (n=67) for 68 weeks; both groups received matching lifestyle counseling. The proportion of participants who achieved an improvement in BMI category from baseline to week 68 was assessed using on-treatment data.

BMI categories, based on United States Centers for Disease Control and Prevention BMI charts, were: normal weight (BMI ≥5th to <85th percentile); overweight (BMI ≥85th to <95th percentile); and obesity class I (OCI; BMI ≥95th percentile).  Severe obesity class II (OCII) and class III (OCIII) are based on a percentage above the 95th percentile cutoff for obesity – OCII is defined as 20% or more above this cutoff and OCIII is defined as 40% or more above this cutoff.

Of 201 adolescents randomised, 62 (31%), 69 (34%) and 69 (34%) were in OCIII, OCII and OCI, respectively; only one participant (0.5%) had overweight and was excluded from this secondary analysis. At randomisation, mean body weight was 107.5 kg and mean BMI was 37.0 kg/m2  (OCII).

At week 68, 74% of participants on semaglutide had an improvement of one or more BMI categories versus 19% on placebo. An improvement of 2 or more BMI categories occurred in 45% of participants treated with semaglutide vs 3% with placebo. Overall, treatment with semaglutide reduced the proportion of participants with the most severe degree of obesity (OCIII) from 37% to 14% after 68 weeks.

By week 68, a total of 45% of participants in the semaglutide arm experienced a reduction in BMI below the clinical cutoff point for obesity (i.e. reached normal weight or overweight) versus 12% of participants in the placebo arm.

The authors conclude: “Once-weekly semaglutide was associated with clinically meaningful improvements in BMI categories compared with placebo across all BMI classes in adolescents with obesity.”

“These results underscore the high degree of clinical effectiveness of semaglutide in adolescents with obesity,” says Dr. Kelly.  “In a practical sense, we see that semaglutide reduced weight to a level below what is defined as clinical obesity in nearly 50% of the teens in our trial, which is historically unprecedented with treatments other than bariatric surgery.”

Author contact – Dr. Aaron S. Kelly, University of Minnesota Medical School, Minneapolis, MN, USA. Please e-mail to arrange interview. Twitter: @AaronKelly_PhD

Another study from STEP TEENS, on liver enzymes, is also presented at this year’s ECO.

For full poster, click here

For STEP TEENS trial published in NEJM in 2022, click here